MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...
Human Genome Sciences announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback